Tricyclic Glucocorticoid Modulators for Bone Protection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current glucocorticoid receptor modulators, such as dexamethasone and prednisolone, are effective but often associated with side effects like bone loss and osteoporosis, necessitating the development of a potent and side-effect mitigated compound.
Innovation Solution
A compound of Formula I, specifically (2R,4αS,10αR)-4α-benzyl-7-((2-methylpyridin-3-yl)carbamoyl)-2-(trifluoromethyl)-1,2,3,4,4α,9,10,10α-octahydrophenanthren-2-yl dihydrogen phosphate, or its salts, is used as a glucocorticoid receptor modulator, which can be administered alone or in compositions with carriers to treat various conditions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional glucocorticoid receptor modulators (dexamethasone, prednisolone) are used to treat inflammation-related conditions, then anti-inflammatory efficacy is improved, but side effects such as bone loss and osteoporosis worsen
Solution Approach 1:
The patent modifies the chemical structure of glucocorticoid receptor modulators by changing molecular parameters - specifically incorporating a tricyclic core structure with specific substituents (R1-R6 positions defined in Formula I) to alter the compound's interaction with the glucocorticoid receptor. This structural parameter change enables maintaining anti-inflammatory efficacy while reducing bone loss and osteoporosis side effects through improved receptor binding characteristics and selective modulation.
Solution Approach 2:
The invention creates a composite molecular structure combining a tricyclic core framework with specific functional groups and substituents (including carbamoyl groups at position 7 and various R1-R6 configurations). This composite molecular design integrates multiple structural elements to achieve both therapeutic efficacy and reduced toxicity, particularly protecting bone density while maintaining anti-inflammatory activity.
2Reliability
If glucocorticoid receptor modulators are used to treat various conditions, then therapeutic efficacy is improved, but side effects worsen
Solution Approach 1:
The patent introduces local structural variations at specific positions in the molecular structure (R1-R6 positions in Formula I, with specific configurations at positions 2, 4α, and 10α). These local quality changes create steric hindrance or enhance binding affinity at particular receptor sites, allowing the compound to achieve therapeutic efficacy while selectively reducing harmful side effects through localized structural optimization.
Solution Approach 2:
The compound acts as an intermediary modulator between the glucocorticoid receptor and the inflammatory response pathway. By incorporating the specific tricyclic structure with carbamoyl groups and defined stereocenters, the compound serves as a selective mediator that activates beneficial anti-inflammatory pathways while blocking harmful downstream effects, thereby reducing side effects while maintaining therapeutic efficacy.
Data Source
AI summary
The present invention is directed to compounds of Formula (I), or salt thereof, which are modulators of the glucocorticoid receptor. The compounds and salts of the invention are useful in the treatment of conditions mediated by glucocorticoid receptor activity.